Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle

Treatment wearing‐off has been reported for calcitonin gene‐related peptide‐pathway monoclonal antibodies, including erenumab, specifically in the last week of the monthly dosing cycle.

[1]  Cheng-Pang Hsu,et al.  Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions , 2022, Cephalalgia : an international journal of headache.

[2]  M. Rettiganti,et al.  Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials , 2022, Headache.

[3]  K. Hirata,et al.  Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study , 2021, Headache.

[4]  S. Silberstein,et al.  Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial , 2021, European journal of neurology.

[5]  Katrina L Devick,et al.  Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine , 2020, Headache.

[6]  M. Robbins,et al.  OnabotulinumtoxinA Wear‐off Phenomenon in the Treatment of Chronic Migraine , 2019, Headache.

[7]  K. Hirata,et al.  A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults , 2019, Headache.

[8]  D. García‐Azorín,et al.  Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. , 2019, Pain medicine.

[9]  P. Goadsby,et al.  A Controlled Trial of Erenumab for Episodic Migraine , 2017, The New England journal of medicine.

[10]  S. Silberstein,et al.  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial , 2017, The Lancet Neurology.

[11]  R. Lipton,et al.  The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results , 2015, Cephalalgia : an international journal of headache.